Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Matthew A. Shanahan is active.

Publication


Featured researches published by Matthew A. Shanahan.


Journal of Medicinal Chemistry | 2012

Optimization of Potent Hepatitis C Virus NS3 Helicase Inhibitors Isolated from the Yellow Dyes Thioflavine S and Primuline

Kelin Li; Kevin J. Frankowski; Craig A. Belon; Ben Neuenswander; Jean Ndjomou; Alicia M. Hanson; Matthew A. Shanahan; Frank J. Schoenen; Brian S. J. Blagg; Jeffrey Aubé; David N. Frick

A screen for hepatitis C virus (HCV) NS3 helicase inhibitors revealed that the commercial dye thioflavine S was the most potent inhibitor of NS3-catalyzed DNA and RNA unwinding in the 827-compound National Cancer Institute Mechanistic Set. Thioflavine S and the related dye primuline were separated here into their pure components, all of which were oligomers of substituted benzothiazoles. The most potent compound (P4), a benzothiazole tetramer, inhibited unwinding >50% at 2 ± 1 μM, inhibited the subgenomic HCV replicon at 10 μM, and was not toxic at 100 μM. Because P4 also interacted with DNA, more specific analogues were synthesized from the abundant dimeric component of primuline. Some of the 32 analogues prepared retained ability to inhibit HCV helicase but did not appear to interact with DNA. The most potent of these specific helicase inhibitors (compound 17) was active against the replicon and inhibited the helicase more than 50% at 2.6 ± 1 μM.


Archive | 2013

Hepatitis C Virus NS3 Helicase Inhibitor Discovery

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank J. Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Table 11, Summary of in vitro ADME properties of ML283 CID 50930730

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Figure 27, Dose response curves for helicase inhibitors used for comparison

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Figure 19, Effect of ML283, CID 50930749, CID 486270, and Telaprevir on Huh7.5 hepatoma cells harboring a stably transfected subgenomic rLuc HCV replicon

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Figure 8, Structures of the isolated components of thioflavine S (T) and primuline (P)

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Figure 17, Summary of the SAR strategy to synthesize analogues based on the hit, P3

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Table A6, Critical reagents for the HCV subgenomic replicon assay

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Table A7, Critical reagents for the cell viability assay

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick


Archive | 2013

Figure 6, Compound attrition of the NCI Mechanistic Set library during screening phases

Kelin Li; Kevin J. Frankowski; Alicia M. Hanson; Jean Ndjomou; Matthew A. Shanahan; Sourav Mukherjee; Rajesh Kolli; William R. Shadrick; Noreena L. Sweeney; Craig A. Belon; Ben Neuenswander; Jill Ferguson; Jeffrey Aubé; Frank Schoenen; Brian S. J. Blagg; David N. Frick

Collaboration


Dive into the Matthew A. Shanahan's collaboration.

Top Co-Authors

Avatar

Alicia M. Hanson

University of Wisconsin–Milwaukee

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Craig A. Belon

New York Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean Ndjomou

University of Wisconsin–Milwaukee

View shared research outputs
Top Co-Authors

Avatar

Kelin Li

University of Kansas

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jill Ferguson

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Noreena L. Sweeney

University of Wisconsin–Milwaukee

View shared research outputs
Researchain Logo
Decentralizing Knowledge